- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 10, 2024Robins Kaplan Ranks Among Top Firms In 2024 American Lawyer Mid-Level Associates Survey
-
September 9, 2024Federal Judge Orders Transformative Reforms at West LA VA Campus in Major Victory for Disabled Veterans
-
September 9, 2024Robins Kaplan Partners Named to 2025 Lawdragon 500 Leading Litigators in America Guide
-
September 17, 2024Hot Torts:
-
September 18, 202422nd Annual Golf Tournament
-
September 19, 2024Best Practices in Institutionalizing Funding within the Law Firm
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
August 22, 2024Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
-
August 13, 2024Playing Dungeons & Dragons Makes Me A Better Lawyer
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches Q2 2012
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
April 04, 2012
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) | Indication | Launch Date |
Avapro | Sanofi Aventis | Irbesartan | Teva | High blood pressure treatment | Apr. 2, 2012 |
Avalide | Sanofi Aventis | Irbesartan-hydrochlorothiazide | Teva | High blood pressure treatment | Apr. 2, 2012 |
Sular Extended Release | Shionogi | Nisoldipine extended release tablets | Prasco | Treatment of high blood pressure | Apr. 2, 2012 |
Mesnex Injection | Baxter Healthcare | Mesna injection | Mylan | Prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis | Apr. 3, 2012 |
Provigil | Cephalon/Teva | Modafinil tablets | Par Pharmaceutical | Wakefulness-promoting agent | Apr. 6, 2012 |
Vancocin HCl Capsules | ViroPharma | Vancomycin hydrochloride | Watson Pharmaceuticals | Treatment of C. difficile-associated diarrhea and enterocolitis | Apr. 10, 2012 |
Vancocin HCl Capsules | ViroPharma | Vancomycin hydrochloride | Akorn | Treatment of C. difficile-associated diarrhea and enterocolitis | Apr. 10, 2012 |
Vancocin HCl Capsules | ViroPharma | Vancomycin hydrochloride | Prasco | Treatment of C. difficile-associated diarrhea and enterocolitis | Apr. 11, 2012 |
Mucinex | Adams Respiratory Therapeutics | Guaifenesin extended-release tablets | Perrigo | Relieve chest congestion and make coughs more productive | Apr. 12, 2012 |
Lescol Capsules | Novartis | Fluvastatin capsules | Mylan | Familial and nonfamilial hypercholesterolemia and mixed dyslipidemia | Apr. 13, 2012 |
Fortamet | Shionogi | Metformin hydrochloride extended-release tablets | Watson Pharmaceuticals | Adjunct to diet and exercise to lower blood glucose | Apr. 19, 2012 |
Zyprexa Tablets | Eli Lilly and Company | Olanzapine | Mylan | Treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar 1 disorder and maintenance treatment of bipolar 1 disorder | Apr. 24, 2012 |
Stalevo | Orion Corporation/Novartis | Levodopa, carbidopa and entacapone | Wockhardt | Treatment of Parkinson's disease | Apr. 24, 2012 |
Doryx | Mayne Pharmaceutical | Dolycycline hyclate delayed-release tablets | Mylan | Antimicrobial | Apr. 30, 2012 |
Plavix | Sanofi Aventis | Clopidogrel tablets | Mylan | Acute coronary syndrome and recent myocardial infarction, stroke or established peripheral arterial disease | May. 17, 2012 |
Prevacide 24HR Capsules | Novartis | Lansoprazole | Perrigo | Treatment of frequent heartburn | May. 18, 2012 |
Requip XL | GlaxoSmithKline | Ropinirole extended-release tablets. | Actavis | Treatment for Parkinson's disease | May. 18, 2012 |
Viramune Tablets | Boehringer Ingelheim | Nevirapine tablets. | Mylan | Combination antiretroviral treatment of HIV-1 infection | May. 23, 2012 |
Lipitor | Pfizer | Atorvastatin calcium tablets | Mylan | Treatment of hypercholesterolemia and mixed dyslipidemia | May. 29, 2012 |
Adalat CC | Bayer | Nifedipine extended-release tablets | Actavis | Treatment of hypertension | May. 30, 2013 |
Requip XL | GlaxoSmithKline | Ropinirole hydrochloride XR | Dr. Reddy's Laboratories | Treatment for Parkinson's disease | Jun. 7 2012 |
Exelon | Novartis | Rivastigmine tartrate Capsules | Breckenridge Pharmaceutical | Treatment of mild to moderate dementia of the Alzheimer's type, and for the treatment of mild to moderate dementia associated with Parkinson's disease | Jun. 14 2012 |
Exelon | Novartis | Rivastigmine tartrate capsules | Alembic Pharmaceuticals | Treatment of mild to moderate dementia of the Alzheimer's type, and for the treatment of mild to moderate dementia associated with Parkinson's disease | Jun. 14 2012 |
Symbyax | Lilly USA | Olanzapine/fluoxetine | Teva | Treatment-resistant depression and bipolar I depression | Jun. 21, 2012 |
Duac Gel | Stiefel Laboratories | Clindamycin phosphate and benzoyl peroxide 1.2%/5% topical gel | Perrigo | Topical treatment of inflammatory acne vulgaris | Jun. 27 2012 |
Thiamine Hydrochloride | Thiamine hydrochloride | Mylan | Thiamine deficiency | Jun. 28 2012 | |
Boniva | Roche | Ibandronate | Dr. Reddy's Laboratories | Treatment of osteoporosis in women after menopause | Jun. 29 2012 |
GENERICally Speaking Summer 2012
Related Publications
Second Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
June 25, 2024
Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
GENERICally Speaking Hatch Waxman Bulletin
June 10, 2024
Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
GENERICally Speaking Hatch Waxman Bulletin
April 30, 2024
Pharmacyclics LLC v. Alvogen Pine Brook LLC
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.